Cambridge University Hospitals group launches experimental drug trial to treat Covid-19
Cambridge University Hospitals group is launching a fast-turnaround experimental drug trial to treat Covid-19.
Two new treatments which tackle aspects of the coronavirus infection are to be tested in the innovative trial which will respond quickly to results from small numbers of patients.
The newly launched trial, known as TACTIC-E (the “E” stands for “experimental”), has been designed to test drugs that have been specifically developed to treat Covid-19 as well as investigating whether combinations of drugs that are already in use can be effective.
The trial will determine whether the major organ complications in severe Covid-19 can be reduced (or prevented) by targeting previously unexplored pathways, via the gut, to reduce the inflammatory response, and via the inner lining of blood vessels, to help increase the amount of oxygen available in the lungs.
One of the drugs to be used in the trial is called EDP1815. The other arm of the trial will involve using two drugs in combination: Dapagliflozin and Ambrisentan.
For more information visit: ITV News
Published May 22, 2020
Latest from CCTU
Calls for more dialysis research following results of landmark UK trial
31-year-old Sameer, who spends more than 70 hours a week on dialysis, says new research results give him hope and highlight the need for more studies in…
Study shows early treatment can prevent long-term complications in Crohn's disease
An Addenbrooke's-led study is the first to provide clear evidence that using more powerful treatments earlier has long-term benefits for people living with…
Targeting the immune system could prevent future heart attacks, Cambridge-led trial suggests
Cambridge researchers have discovered that an existing therapy which boosts protective immune cells in people who have recently had heart attacks reduces…
